MARKET

NAMS

NAMS

NewAmsterdam Pharma Company N.V
NASDAQ
23.15
-2.49
-9.70%
Opening 14:48 09/09 EDT
OPEN
25.35
PREV CLOSE
25.63
HIGH
25.53
LOW
23.08
VOLUME
905.83K
TURNOVER
--
52 WEEK HIGH
42.21
52 WEEK LOW
23.05
MARKET CAP
2.77B
P/E (TTM)
-10.7782
1D
5D
1M
3M
1Y
5Y
1D
NewAmsterdam Pharma: Potential Coupled With Uncertainty
Seeking Alpha · 1d ago
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and NewAmsterdam Pharma Company (NAMS)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS), Merck & Company (MRK) and Royalty Pharma (RPRX)
TipRanks · 1d ago
NewAmsterdam Pharma Price Target Maintained With a $52.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS)
TipRanks · 1d ago
HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target
Benzinga · 1d ago
Biggest stock movers Tuesday: ZIM, NVS, and more
Seeking Alpha · 1d ago
More
About NAMS
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

Webull offers NewAmsterdam Pharma Company NV stock information, including NASDAQ: NAMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NAMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NAMS stock methods without spending real money on the virtual paper trading platform.